Trials / Active Not Recruiting
Active Not RecruitingNCT06712615
Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
A Phase II Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Safety of PG-102(MG12) Compared With Placebo in Subjects With Obesity and in Subjects With Type 2 Diabetes Mellitus (T2DM)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- ProGen. Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, therapeutic exploratory study designed to evaluate the safety and efficacy of PG-102 compared with placebo. Part A includes Cohort A, comprising participants with type 2 diabetes mellitus (T2DM). Part B includes two cohorts: Cohort B1, enrolling participants with obesity, and Cohort B2, enrolling participants with both obesity and T2DM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PG-102 | * Participants will receive PG-102 by subcutaneous (SC) injection. * Other Names: MG12 |
| OTHER | Placebo | Participants will receive placebo by SC injection |
Timeline
- Start date
- 2024-12-05
- Primary completion
- 2025-10-30
- Completion
- 2025-10-30
- First posted
- 2024-12-02
- Last updated
- 2025-07-11
Locations
14 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06712615. Inclusion in this directory is not an endorsement.